Juul M. P. A. van Den Reek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juul M. P. A. van Den Reek has a total of 351 co-authors. Here are the top co-authors by number of shared publications:
- Elke M. G. J. de Jong
Department of Dermatology Radboud University Medical Centre Nijmegen the Netherlands
36 shared publications E.M.G.J. de Jong
8 shared publications- Hans Groenewoud
Department for Health Evidence Radboud University Nijmegen the Netherlands
7 shared publications M.M.B. Seyger
7 shared publications- Marieke Martha Benedicta Seyger
Department of Dermatology Radboud University Medical Centre Nijmegen the Netherlands
7 shared publications - Lara S. van der Schoot
Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands
6 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by Elsevier in JAAD International
Experiences and burden of people living with generalized pustular psoriasis: a qualitative study
- 7 November 2026
- Published by Elsevier in JAAD International
Open AccessExperiences and burden of people living with generalized pustular psoriasis: a qualitative study
- Open Access
- 3 October 2026
- Published by Elsevier in JID Innovations
- Vol. 7 (1)
A survival guide for drug survival studies in dermatology: Methodological approaches and best practices
- 3 October 2026
- Published by Elsevier in JID Innovations
- Vol. 7 (1)
Open AccessA survival guide for drug survival studies in dermatology: Methodological approaches and best practices
- Open Access
- 9 September 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (9)
Future Integration of Biomarkers for Inflammatory Skin Diseases Into Daily Practice: A Survey Among a Multifaceted Group of Patients and Dermatological Care Providers
Successful implementation of dermatological biomarkers depends on early understanding of clinical needs and adoption barriers. Yet, research on these factors as perceived by dermatological care providers (DCPs) is scarce and perspectives of patients are largely underexplored. This survey study among patients and DCPs assessed biomarker needs and adoption barriers and facilitators for five inflammatory skin diseases: psoriasis (PsO), atopic dermatitis (AD), hidradenitis suppurativa (HS), cutaneous lupus erythematosus (CLE) and chronic spontaneous urticaria (CSU). In total, the study population consisted of 591 patients and 99 DCPs. Across all skin diseases, both groups mainly prioritized a biomarker for prediction of therapeutic response, however, DCPs prioritized this substantially more often than patients, especially for PsO (79.8% vs. 31.3% resp.), AD (68.7% vs. 37.1% resp.) and HS (66.7% vs. 34.4% resp.). Notably, a biomarker for the prediction of the risk to develop comorbidities was prioritized relatively often by patients (7.0%–19.4%), whereas DCPs only substantially prioritized this for CLE (14.1%). To enhance implementation, patients must ideally be able to undergo biomarker collection nearby their homes (travel time < 1 h) with complete reimbursement. For DCPs it is important that the biomarker is well validated, non‐invasive and measurable during regular visits with preferably a short sampling time.
- 9 September 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (9)
Open AccessFuture Integration of Biomarkers for Inflammatory Skin Diseases Into Daily Practice: A Survey Among a Multifaceted Group of Patients and Dermatological Care Providers
Successful implementation of dermatological biomarkers depends on early understanding of clinical needs and adoption barriers. Yet, research on these factors as perceived by dermatological care providers (DCPs) is scarce and perspectives of patients are largely underexplored. This survey study among patients and DCPs assessed biomarker needs and adoption barriers and facilitators for five inflammatory skin diseases: psoriasis (PsO), atopic dermatitis (AD), hidradenitis suppurativa (HS), cutaneous lupus erythematosus (CLE) and chronic spontaneous urticaria (CSU). In total, the study population consisted of 591 patients and 99 DCPs. Across all skin diseases, both groups mainly prioritized a biomarker for prediction of therapeutic response, however, DCPs prioritized this substantially more often than patients, especially for PsO (79.8% vs. 31.3% resp.), AD (68.7% vs. 37.1% resp.) and HS (66.7% vs. 34.4% resp.). Notably, a biomarker for the prediction of the risk to develop comorbidities was prioritized relatively often by patients (7.0%–19.4%), whereas DCPs only substantially prioritized this for CLE (14.1%). To enhance implementation, patients must ideally be able to undergo biomarker collection nearby their homes (travel time < 1 h) with complete reimbursement. For DCPs it is important that the biomarker is well validated, non‐invasive and measurable during regular visits with preferably a short sampling time.
- Open Access
- 10 August 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1)
Patients’ and clinicians’ perspectives on telemedicine to monitor patients on systemic treatment for psoriasis or atopic dermatitis - a mixed methods study
Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases, and due to the chronic nature of these diseases lifelong treatment is often required. In many countries, patients with ps...
- 10 August 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1)
Open AccessPatients’ and clinicians’ perspectives on telemedicine to monitor patients on systemic treatment for psoriasis or atopic dermatitis - a mixed methods study
Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases, and due to the chronic nature of these diseases lifelong treatment is often required. In many countries, patients with ps...
- Open Access
- 1 June 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Psoriasis Triggers and Disease Activity: Analysis of Survey Data from the PSODEEP1 Study
Numerous patients with psoriasis will associate disease triggers to changes in disease activity over time. Modern treatments induce remission, but relapse is common if the treatment is stopped. Exploring patients’ first-hand experiences is a key starting point to identify triggers that may influence disease relapse. A cross-sectional digital questionnaire was distributed to 2716 individuals with psoriasis in Chile, Denmark, Sweden, and the Netherlands. 71% of participants reported psoriatic disease triggers. Triggers were classified into 24 subgroups dominated by stress (55.3%), infections (17.7%) and alcohol (10.8%). The majority (65%) of the participants experienced seasonal variation in disease activity, and approximately half reported fluctuating disease activity with periods of flare-ups. The self-reported trigger prevalence varied by gender, disease manifestation (skin psoriasis and/or psoriatic arthritis), and country of residence. The female participants more often reported stress and infections as triggers. Alcohol consumption is more often reported as a trigger in males. Chileans more often reported stress and less frequently reported infections as triggers. Insights into patient-reported disease variations and triggers can be used to aid patient-physician conversations and patient phenotyping during routine clinical practice. Trigger assessment and management could potentially contribute to patient counselling and motivate lifestyle changes.
- 1 June 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessPsoriasis Triggers and Disease Activity: Analysis of Survey Data from the PSODEEP1 Study
Numerous patients with psoriasis will associate disease triggers to changes in disease activity over time. Modern treatments induce remission, but relapse is common if the treatment is stopped. Exploring patients’ first-hand experiences is a key starting point to identify triggers that may influence disease relapse. A cross-sectional digital questionnaire was distributed to 2716 individuals with psoriasis in Chile, Denmark, Sweden, and the Netherlands. 71% of participants reported psoriatic disease triggers. Triggers were classified into 24 subgroups dominated by stress (55.3%), infections (17.7%) and alcohol (10.8%). The majority (65%) of the participants experienced seasonal variation in disease activity, and approximately half reported fluctuating disease activity with periods of flare-ups. The self-reported trigger prevalence varied by gender, disease manifestation (skin psoriasis and/or psoriatic arthritis), and country of residence. The female participants more often reported stress and infections as triggers. Alcohol consumption is more often reported as a trigger in males. Chileans more often reported stress and less frequently reported infections as triggers. Insights into patient-reported disease variations and triggers can be used to aid patient-physician conversations and patient phenotyping during routine clinical practice. Trigger assessment and management could potentially contribute to patient counselling and motivate lifestyle changes.
- Open Access
- 25 May 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (9) , 1910-1912
Angioedema in Primary Care: Disease Course and Its Relation to ACE Inhibitor Use
- 25 May 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (9) , 1910-1912
Open AccessAngioedema in Primary Care: Disease Course and Its Relation to ACE Inhibitor Use
- Open Access
- 21 April 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (9) , 1449-1459
International consensus on dose reduction of biologics for patients with psoriasis: The DR . Delphi study
Background: Dose reduction (DR) of biologics for psoriasis is already applied in clinical practice but without clear guidelines, while dermatologists addressed the need for guidance. An international consensus may contribute to optimal implementation of biologic DR in clinical psoriasis practices. Objectives: This consensus study aims for international consensus on DR of biologics in adult patients with psoriasis among dermatologists worldwide. Methods: An international, modified eDelphi consensus study was performed among dermatologists worldwide. A total of 11 statements on biologic DR were generated by the international steering committee, based on a previous literature review. Invitations were distributed via international dermatological societies. Participants rated their level of agreement per statement on a 9‐point Likert scale. A maximum of three consensus rounds and one (digital) consensus meeting were expected. Statements reached consensus if ≥70% agreed and <15% disagreed; otherwise, statements were revised for a next consensus round. Results: In total, 62 dermatologists from Europe, South America, Asia, North America, Africa and Australia completed the eDelphi. After one round, 9 out of 11 statements reached consensus. The remaining 2 statements were adapted and reached consensus in the second round. Participants agreed on criteria when to consider and initiate/(dis)continue DR and on a two‐step DR algorithm for adalimumab, etanercept and ustekinumab. Participants agreed that this two‐step DR strategy can also be considered for IL‐17 and IL‐23 inhibitors while awaiting more scientific evidence on DR of these newer biologics. Conclusions: Dermatologists worldwide reached consensus on when and how to initiate and (dis)continue DR of biologics, and on a two‐step DR algorithm for adalimumab, etanercept and ustekinumab in adult patients with psoriasis. DR of IL‐17 and IL‐23 inhibitors was deemed feasible; however, underlying evidence is still limited. This first international consensus provides essential information for uptake and implementation of biologic DR for psoriasis on a global scale.
- 21 April 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (9) , 1449-1459
Open AccessInternational consensus on dose reduction of biologics for patients with psoriasis: The DR . Delphi study
Background: Dose reduction (DR) of biologics for psoriasis is already applied in clinical practice but without clear guidelines, while dermatologists addressed the need for guidance. An international consensus may contribute to optimal implementation of biologic DR in clinical psoriasis practices. Objectives: This consensus study aims for international consensus on DR of biologics in adult patients with psoriasis among dermatologists worldwide. Methods: An international, modified eDelphi consensus study was performed among dermatologists worldwide. A total of 11 statements on biologic DR were generated by the international steering committee, based on a previous literature review. Invitations were distributed via international dermatological societies. Participants rated their level of agreement per statement on a 9‐point Likert scale. A maximum of three consensus rounds and one (digital) consensus meeting were expected. Statements reached consensus if ≥70% agreed and <15% disagreed; otherwise, statements were revised for a next consensus round. Results: In total, 62 dermatologists from Europe, South America, Asia, North America, Africa and Australia completed the eDelphi. After one round, 9 out of 11 statements reached consensus. The remaining 2 statements were adapted and reached consensus in the second round. Participants agreed on criteria when to consider and initiate/(dis)continue DR and on a two‐step DR algorithm for adalimumab, etanercept and ustekinumab. Participants agreed that this two‐step DR strategy can also be considered for IL‐17 and IL‐23 inhibitors while awaiting more scientific evidence on DR of these newer biologics. Conclusions: Dermatologists worldwide reached consensus on when and how to initiate and (dis)continue DR of biologics, and on a two‐step DR algorithm for adalimumab, etanercept and ustekinumab in adult patients with psoriasis. DR of IL‐17 and IL‐23 inhibitors was deemed feasible; however, underlying evidence is still limited. This first international consensus provides essential information for uptake and implementation of biologic DR for psoriasis on a global scale.
- Open Access
- 1 March 2026
- Vol. 40 (3) , 339-340
Bridging theory and practice in model-informed precision dosing of medication in inflammatory skin diseases.
- 1 March 2026
- Vol. 40 (3) , 339-340
Open AccessBridging theory and practice in model-informed precision dosing of medication in inflammatory skin diseases.